Author's response to reviews Title: Host-Derived RANKL is Responsible for Osteolysis in C4-2 Human Prostate Cancer Xenograft Model of Experimental Bone Metastases Authors:

Host-Derived RANKL is Responsible for Osteolysis in C4-2 Human Prostate Cancer Xenograft Model of Experimental Bone Metastases

Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle

Bone is a common site for cancer metastasis. To create space for their growth, cancer cells stimulate bone resorbing osteoclasts. Cytokine RANKL is a key osteoclast activator, while osteoprotegerin (OPG) is a RANKL decoy receptor and an inhibitor of osteoclastogenesis. Consistently, systemic application of OPG decreases metastatic tumor burden in bone. However, OPG produced locally by cancer ce...

Evaluation of Strontium-89 in palliative treatment of widespread and painful bone metastases due to breast and prostate cancer [Persian]

Treatment of bone metastases comprises over 10% of the workload of a radiation-oncology center. Bone metastases produce severe pain and immobility, necessitate narcotic use, and reduce the quality of life. A good palliative treatment must be complete, free from side effects and fast; Thus we decided to evaluate Strontium-89 (89Sr) effectivity for palliation of breast and prostate cancer b...

The Role of Rankl in Prostate Cancer Progression and Bone Metastasis

This study focused on the role of RANKL in prostate cancer EMT progression and metastasis. Activation of RANK, a receptor activator of NF-κB, by its ligand RANKL, in a paracrine manner is responsible for osteoclast differentiation and bone remodeling. RANK activation in cancer cells, however, is thought to be promoted by both autocrine and paracrine mechanisms because RANKL has been shown to be...

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer

www.amepc.org/tau © Translational Andrology and Urology. All rights reserved. In a large multicenter phase 3 randomized controlled trial published in Lancet, Smith and colleagues highlight a potential new indication for denosumab for patients with hormone refractory prostate cancer (1). Already approved for prevention of skeletal-related events in the setting of bone metastases in solid tumors ...